Fahed Hamadeh, MD
Rheumatology · Oklahoma City, OKNPI 1194760918
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.3%), food and beverage and education — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 66.3% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $2,808, 4.3 times the $649 reported in 2019.
Across 106 payments — averaging $71.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- AbbVie$793
- GSK$667
- Janssen Scientific Affairs, LLC$348
- Amgen$287
- Aurinia Pharma U.S., Inc.$200
- plus $269 from 4 others
Across 36 payments — averaging $8711.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$241K
- Sun Pharmaceutical Industries Inc.$41K
- E.r. Squibb & Sons, L.L.C.$31K
What the payments were for
- Consulting fees$3,90051%
- Speaking & faculty fees$2954%
- Travel & lodging$2653%
- Food & beverage$2,58634%
- Education$5577%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 38 | $5,040 |
| AbbVie(2 entities) | 21 | $793 |
| GSK | 32 | $667 |
| Janssen Scientific Affairs, LLC | 4 | $348 |
| Amgen | 4 | $287 |
| Aurinia Pharma U.S., Inc. | 2 | $200 |
| AstraZeneca | 2 | $119 |
| E.r. Squibb & Sons, L.L.C. | 1 | $108 |
| Bristol Myers Squibb | 1 | $21 |
| Nalu Medical, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,603 in reported general payments places this provider in the 60th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 312 | $2,428,177 |
| Enbrel SureclickEtanercept | 253 | $1,919,346 |
| RinvoqUpadacitinib | 208 | $1,383,807 |
| BenlystaBelimumab | 95 | $447,706 |
| Orencia ClickjectAbatacept | 62 | $367,484 |
| Skyrizi PenRisankizumab-Rzaa | 16 | $320,633 |
| SimponiGolimumab | 47 | $281,189 |
| Xeljanz XrTofacitinib Citrate | 36 | $207,293 |
| Humira(Cf)Adalimumab | 25 | $171,121 |
| TremfyaGuselkumab | 12 | $160,756 |
| Cimzia (2 Pack)Certolizumab Pegol | 28 | $158,317 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 19 | $146,105 |
| Actemra ActpenTocilizumab | 47 | $146,080 |
| Cosentyx Sensoready PenSecukinumab | 14 | $130,874 |
| Simponi AriaGolimumab | 12 | $118,328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $793 | $1,554,928233 claims |
| Johnson & JohnsonSimponi, Tremfya, Simponi Aria | $5,040 | $560,27371 claims |
| GSKBenlysta | $667 | $447,70695 claims |
| AmgenEnbrel, Otezla | $287 | $222,11136 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $108 | $74,41813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 67 rheumatology providers in Oklahoma.
Other rheumatology in Oklahoma City
- Joan MerrillOklahoma City$864K
- Latisha HeinlenOklahoma City$675K
- Mohammad KhanOklahoma City$94K
- Cristina ArriensOklahoma City$82K
- John GoetzingerOklahoma City$18K
- Robert ArthurOklahoma City$16K
- Muhammad GillanOklahoma City$16K
- William SchnitzOklahoma City$15K
- Judith JamesOklahoma City$15K
- Amanda TitusOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.